微信小陈
微信小章| 产品名称： | 55-36 |
|---|---|
| 商品货号： | TS212830 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | Suzanne Epstein that reacts with the gp120 of HIV-1. In ELISA the antibody reacts strongly with rgp120 IIIB. In immunofluorescence assays, it binds weakly to cell surface expressed gp160 and also shows weak cross-reactivity by ELISA with gp120 MN (an isolate not used during immunization). The antibody does not bind to the gp120 synthetic peptides that were used to map antibody reactivity and was not able to cross block any other antibodies in the panel. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Spleen cells were fused with Sp2/0-Ag14 myeloma cells. 55-36 is one of a panel of antibodies developed by Dr. Suzanne Epstein that reacts with the gp120 of HIV-1. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against human immunodeficiency virus 1 (HIV-1) gp120 |
| Cellular Products： | immunoglobulin; monoclonal antibody; against human immunodeficiency virus 1 (HIV-1) gp120 |
| Tumorigenic： | Yes |
| Effects： | Yes, in BALB/c mice |
| Comments： | Animals were sequentially immunized with recombinant gp120 (rgp120) from three different nonglycosylated isolates of HIV-1 (IIIB, SF2, and Z6). Spleen cells were fused with Sp2/0-Ag14 myeloma cells. 55-36 is one of a panel of antibodies developed by Dr. Suzanne Epstein that reacts with the gp120 of HIV-1. In ELISA the antibody reacts strongly with rgp120 IIIB. In immunofluorescence assays, it binds weakly to cell surface expressed gp160 and also shows weak cross-reactivity by ELISA with gp120 MN (an isolate not used during immunization). The antibody does not bind to the gp120 synthetic peptides that were used to map antibody reactivity and was not able to cross block any other antibodies in the panel. |
| Complete Growth Medium： | The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell-culture-grade water and supplemented with 1.5 g/L sodium bicarbonate. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing： | Culture can be maintained by addition of fresh Medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 x 105 viable cells/mL.xa0 Maintain cultures at a cell concentration between 1 x 105 and 1 x 106 cells/mL. Medium Renewal: Every 2 to 3 days |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 |
| Name of Depositor： | SL Epstein |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Reeves JP, et al. Mouse monoclonal antibodies to human immunodeficiency virus glycoprotein 120 generated by repeated immunization with glycoprotein 120 from a single isolate, or by sequential immunization with glycoprotein 120 from three isolates. Hybridoma 14: 235-242, 1995. PubMed: 7590785 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |